Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness
- Details
- Category: Pfizer
Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients.
GSK launches new specialist unit to research and develop medicines for rare diseases
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has announced the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a significant unmet medical need.
Strong operating performance for Roche in 2009
- Details
- Category: Roche
The total Roche Group's sales grew by 10% in local currencies (8% in Swiss francs; 7% in US dollars) to 49.1 billion Swiss francs, with the Pharmaceuticals Division accounting for 80% of Group sales and the Diagnostics Division contributing 20%. Sales growth in both divisions exceeded market growth.
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today reported financial results for fourth-quarter and full-year 2009. On October 15, 2009, Pfizer completed the acquisition of Wyeth and, consequently, fourth-quarter and full-year 2009 results include the legacy Wyeth operations from the acquisition date through Pfizer's domestic and international year-ends.
VYVANSE® - new ADHD treatment option - now available in Canada
- Details
- Category: Shire
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
Roche establishes new medical research hub in Singapore
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) will enter into a strategic alliance with Singapore's scientific and medical institutions to set up a major new translational research hub in Singapore. This "Hub for Translational Medicine" aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients.
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
- Details
- Category: Eli Lilly and Company
In the fourth quarter of 2009, worldwide total revenue was $5.934 billion, an increase of 14 percent compared with the fourth quarter of 2008. This 14 percent revenue growth was comprised of an increase of 7 percent due to higher volume, 3 percent due to higher prices, and 3 percent due to the impact of foreign exchange rates (numbers do not add due to rounding).
More Pharma News ...
- AstraZeneca Fourth Quarter and Full Year Results 2009
- New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas
- Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter
- Novartis achieves record results in 2009
- Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII
- Bayer to discontinue the LIPLONG study
- Novo Nordisk receives approval for Victoza® in Japan